Skip to main content
UK Edition

Saturday, 15 August 2026

Trade News UK

The latest UK news, business, transport and more

Home / Economy

Economy

Dow Jones futures gain on tech-driven rally

Dow Jones futures rise 0.19% to trade around 54,600 during European hours on Thursday. Meanwhile, S&P 500 futures gain 0.09% to trade near 7,760, while Nasdaq 100 futures decline 0.35%, trading near 29,510.

Why is Hikma Pharmaceuticals stock surging today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high ri…

Gold: Breakout extends as yields ease – OCBC

OCBC’s Christopher Wong and Sim Moh Siong highlight a sharp rebound in Gold as easing Middle East tensions weighed on Oil and US Treasury yields, softening the US Dollar.

US Dollar: Wait-and-see mood before payrolls – ING

ING’s FX Strategist Francesco Pesole notes improved Gulf-related risk sentiment has weighed slightly on the Dollar, but stable Federal Reserve rate expectations remain supportive. With US payrolls due tomorrow, he argue…

Green notice 2026/02

Following the publication of Green Notice 2026/01 and the associated consultation on the proposal to discontinue the collection and publication of Form BN data, we are issuing this follow up notice to provide an update …

Serco shares rise after profit increase and buyback boost

Defence sector spending as a percentage of GDP has risen steadily in key economies over the past decade, with governments allocating larger budgets toward modernising military capabilities and acquiring advanced weapons…

Palantir Earnings Provide Hope for the Software Sector

August 5, 2026, 3:53 AM EDT.IPOs such as SpaceX and ChangXin Memory Technologies have generated worldwide interest, particularly across the tech and AI sectors. Still, with founders trying to maximize returns and invest…

Moderna wins U.S. FDA approval for first mRNA-based flu vaccine

Today is the deadline the FDA set itself to issue a verdict on the first mRNA-based seasonal influenza vaccine in American history — but adults 50 and older who are hoping to switch to Moderna's mFlusiva for the coming …